ABROS

Abros Biosciences is a biotechnology company focused on the discovery and development of novel small molecule therapeutics for cancer treatment, with a primary emphasis on the DNA Damage Response (DDR) pathway. The company's lead program targets Ubiquitin-specific protease 1 (USP1), an enzyme critical for DNA repair in certain cancer cells. By inhibiting USP1, Abros aims to exploit synthetic lethality in tumors with specific genetic vulnerabilities, such as BRCA mutations. This approach is designed to provide more effective and targeted treatment options for patients with difficult-to-treat cancers. Headquartered in New Jersey, the company is supported by a team of experienced pharmaceutical researchers and leading venture capital firms.